Cognitive Hyper-performance - Effects of Stimulating Substances in Chess-players (CHESS)

Phase I Study About Effects of Caffeine, Methylphenidate, Modafinil and Placebo on Cognitive Performance of Chess Players.

Effects of caffeine, methylphenidate, modafinil and placebo on cognitive performance of chess players in chess games and neuropsychiatric standardized tests. We hypothesize that substances will change cognitive performance in chess players leading to changed results in chess games and neuropsychiatric tests.

Study Overview

• Status: Completed
• Conditions: Cognitively Healthy Subjects Influenced by Psychoactive Drugs
• Intervention / Treatment: Drug: placebo; Drug: Drugs use: methylphenidate; Drug: Drug use: modafinil; Drug: caffeine

• Study Type: Interventional
• Enrollment (Actual): 40
• Phase: Phase 1

Contacts and Locations

Study Locations

• Germany
  • Mainz, Germany, 55131
    • Department of Psychiatry and Psychotherapy

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 60 years (Adult)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: Male

Description

Inclusion Criteria:

• male
• 18-60 years old
• existence of ELO-number

Exclusion Criteria:

• physical diseases (e.g. diabetes mellitus, etc.) with necessity of using prescription drugs
• psychiatric diseases (e.g. psychosis, bipolar disorders, etc.) with necessity of using prescription drugs
• addiction of psychoactive substances
• smoker or quitter (< 5 years)
• use of more than 5 cups of coffee per day
• irregular day-night-rhythm (e.g. shift workers)

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Health Services Research
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: Triple

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: placebo	Drug: placebo; placebo
Experimental: Methylphenidate	Drug: Drugs use: methylphenidate; 40 mg tablets
Experimental: modafinil	Drug: Drug use: modafinil; 40 mg tablets
Experimental: caffeine	Drug: caffeine; 400 mg

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Chess games (win/ lose/ tie)	two years

Secondary Outcome Measures

Outcome Measure	Time Frame
time period for decision of chess games	results of ches games
Cognitive performance measured with standardized neuropsychiatric tests (Tower of Hanoi, Trail-Making test, Stroop-Test, Psycho-Motor-Vigilance test, Wisconsin-Card-Sorting-Test, Balloon Analog Risk Task)	outcome of tests
measuring of risk taking behaviour, motivation, mood using standardized questionnaires	outcome of tests
adverse events	type of adverse events

Collaborators and Investigators

• Sponsor: K. Lieb

Study record dates

Study Major Dates

• Study Start: May 1, 2011
• Primary Completion (Actual): April 1, 2013
• Study Completion (Actual): April 1, 2013

Study Registration Dates

• First Submitted: May 25, 2011
• First Submitted That Met QC Criteria: April 17, 2013
• First Posted (Estimate): April 18, 2013

Study Record Updates

• Last Update Posted (Estimate): April 18, 2013
• Last Update Submitted That Met QC Criteria: April 17, 2013
• Last Verified: April 1, 2013

More Information

Terms related to this study

• Keywords: chess, cognition
• Additional Relevant MeSH Terms: Physiological Effects of Drugs; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Purinergic Antagonists; Purinergic Agents; Neurotransmitter Uptake Inhibitors; Membrane Transport Modulators; Dopamine Agents; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 CYP3A Inducers; Dopamine Uptake Inhibitors; Phosphodiesterase Inhibitors; Purinergic P1 Receptor Antagonists; Central Nervous System Stimulants; Wakefulness-Promoting Agents; Methylphenidate; Caffeine; Modafinil
• Other Study ID Numbers: 1234 (Department of Defense)